Zobrazeno 1 - 10
of 263
pro vyhledávání: '"V. Nikolaou"'
Autor:
E. Papadavid, M. Koumourtzis, V. Nikolaou, K. Lampadaki, L. Marinos, A. Patsatsi, E. Georgiou, M. Dalamaga, A. Stratigos
Publikováno v:
Journal of the European Academy of Dermatology and Venereology. 36:1751-1757
Chlormethine gel is a skin-directed therapy used for patients with mycosis fungoides (MF) that showed a favourable risk/benefit profile in a randomized clinical trial. Currently, data on chlormethine gel use in real-world settings are limited.The aim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da6a6e3e1d7c27cd2b1da36df4881df2
https://doi.org/10.1111/jdv.18183
https://doi.org/10.1111/jdv.18183
Autor:
V. Nikolaou, A. J. Stratigos
Publikováno v:
Journal of the European Academy of Dermatology and Venereology. 37:851-852
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5fa445db47818edbb7a16f30bbce29e6
https://doi.org/10.1111/jdv.19010
https://doi.org/10.1111/jdv.19010
Autor:
Florentia Dimitriou, Pietro Quaglino, Theodoros Iliakis, P L Ortiz-Romero, Marianna Dalamaga, V. Nikolaou, Martine Bagot, S. Engelina, Stefanie Porkert, E. Papadavid, Vassiliki Pappa, J. Scarisbrick, Constanze Jonak, Emmilia Hodak, C Vico, Emmanuella Guenova, R Guiron, E Kapniari, Antonio Cozzio
Publikováno v:
British Journal of Dermatology. 185:1035-1044
BACKGROUND Brentuximab vedotin (BV) was approved as a therapy for mycosis fungoides (MF) based on the ALCANZA trial. Little real-world data, however, are available. OBJECTIVES To evaluate the efficacy and safety of BV in patients with MF/Sezary Syndr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b42e61e8fb4bb4ef2e0b723be4e00fe3
https://doi.org/10.1111/bjd.20588
https://doi.org/10.1111/bjd.20588
Autor:
Z. Apalla, V. Nikolaou, D. Fattore, G. Fabbrocini, A. Freites‐Martinez, P. Sollena, M. Lacouture, L. Kraehenbuehl, A. Stratigos, K. Peris, E. Lazaridou, B. Richert, E. Vigarios, J. Riganti, B. Baroudjian, A. Filoni, R. Dodiuk‐Gad, C. Lebbé, V. Sibaud
The introduction of immune checkpoint inhibitors (ICIs) opened a new era in oncologic therapy. The favourable profile of ICIs in terms of efficacy and safety can be overshadowed by the development of immune-related adverse events (irAEs). Dermatologi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42aef38e1949b2845772c184ecf65721
http://hdl.handle.net/10807/197825
http://hdl.handle.net/10807/197825
Autor:
S Kallambou, E Panou, Alexandros Stratigos, Polytimi Sidiropoulou, V. Nikolaou, Maria A. Gerochristou, L. Marinos
Publikováno v:
Journal of the European Academy of Dermatology and Venereology. 36
We are living an ongoing global COVID-19 pandemic which is associated with a considerable number of fatal cases worldwide1 . Vaccines are the promising solution to minimise the problem amongst cancer patients, however there are limitations to be cons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b8e854fdff4919d8719ae76b04bfc60
https://doi.org/10.1111/jdv.17736
https://doi.org/10.1111/jdv.17736
Autor:
K Lampadaki, A Vaiopoulos, V Bizimi, D Filippiadis, S Grigoriadis, M Koumourtzis, V Nikolaou, A Bouchla, P Tsirigotis, V Pappa, L Marinos, E Papadavid
Publikováno v:
European Journal of Cancer. 173:S39
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::710e0aa238bbdfd7ced9938f5c72ba26
https://doi.org/10.1016/s0959-8049(22)00631-1
https://doi.org/10.1016/s0959-8049(22)00631-1
Autor:
MR Koumourtzis, I Georgakopoulos, K Lampadaki, A Vaiopoulos, L Marinos, K Platoni, A Mpouhla, E Kypraiou, V Nikolaou, P Tsirigotis, V Kouloulias, V Pappa, A Stratigos
Publikováno v:
European Journal of Cancer. 173:S46
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0594c131aaf4c0efd4faa48369c8ba4
https://doi.org/10.1016/s0959-8049(22)00644-x
https://doi.org/10.1016/s0959-8049(22)00644-x
Autor:
Konstantinos Konstantopoulos, A. Velissari, G. Daikos, K.V. Argyropoulos, Alexandros Stratigos, Eleftheria Lakiotaki, V. Nikolaou, Marina P. Siakantaris
Publikováno v:
Journal of the European Academy of Dermatology and Venereology : JEADVReferences. 35(11)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73b2248df2e442bc86af6184ff5a0559
https://pubmed.ncbi.nlm.nih.gov/34173274
https://pubmed.ncbi.nlm.nih.gov/34173274
Background Brentuximab vedotin (BV) was approved as a therapy for mycosis fungoides (MF) based on the ALCANZA trial. Little real-world data, however, are available. Objectives To evaluate the efficacy and safety of BV in patients with MF/Sezary Syndr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::fe4b925e9f11f70c72e03c81b90ad3a0
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3030791
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3030791
Introduction: Several studies have implicated the PIK3/AKT pathway in the pathophysiology of cancer progression as its activation seems to be aberrant in several forms of cancer. The purpose of the present systematic review is to evaluate the impact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::5c4dbeb7803db5999c69fbd86b2e3d19
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3120546
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3120546